New drug aims to strengthen bones in people with brittle bone disease

NCT ID NCT07557446

First seen May 06, 2026 · Last updated May 08, 2026 · Updated 1 time

Summary

This study tests a new medicine called AGA2115 in 48 Chinese adults and teenagers with osteogenesis imperfecta (brittle bone disease) types I, III, or IV. The goal is to see if different doses are safe and can improve bone density. Participants will receive one of three dose schedules and be monitored for side effects and bone strength changes over 12 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOGENESIS IMPERFECTA (OI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital of Soochow University

    Suzhou, Jiangsu, 215025, China

    Contact

  • Chinese Academy of Medical Sciences, Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100005, China

    Contact

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, 200233, China

    Contact

  • The University of Hong Kong-Shenzhen Hospital

    Shenzhen, Guangdong, 518053, China

    Contact

Conditions

Explore the condition pages connected to this study.